Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

Considering Benzbromarone as First-Line Therapy for Gout

Arthritis & Rheumatology  |  December 1, 2022

In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone (not approved in the U.S.), a renal urate transporter 1 inhibitor, with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.

Filed under:ConditionsDrug UpdatesGout and Crystalline ArthritisResearch Rheum Tagged with:Arthritis & RheumatologybenzbromaroneFebuxostatGouthyperuricemiaResearch

Duke Researchers Create a Type 1, Type 2 Lupus Disease Model

Catherine Kolonko  |  November 29, 2022

A new disease model for lupus tackles issues with fatigue and other serious conditions that, although quite common among patients, get less attention because they fall outside classic symptoms associated with inflammation, a debilitating force behind systemic lupus erythematosus (SLE). The model features subtypes to cate­gorize two main groups of symptoms into type 1, typically…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:fatiguelupus disease modellupus subtypes

Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis

Ashley Krivohlavek  |  November 29, 2022

PHILADELPHIA—“At age 12, I was diagnosed with psoriasis (PsO), followed by a diagnosis of psoriatic arthritis (PsA) at age 30,” said Ashley Krivohlavek of Oklahoma City in a poster presentation at ACR Convergence 2022. “I’m now 38.”   Ms. Krivohlavek’s Story In 2020, I had been on an infused biologic for 18 months, but my…

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsOpinionPatient PerspectivePsoriatic ArthritisSpeak Out Rheum Tagged with:ACR Convergence 2022ACR Convergence 2022 – PsApatient perspectivesPsoriatic Arthritis

From Denial of Spondyloarthritis to a Support Group Leader & Medical Doctor of Rheumatology: A Patient’s Perspective

Shung Ming Chiu, MD  |  November 29, 2022

PHILADELPHIA—“My symptoms started in the final year of medical school, and at that stage I believed I was strong enough to fight my condition,” said Shung Ming Chiu, MD, in a poster presentation at ACR Convergence 2022. “Later, I realized that it’s not [about] fighting [but] rather accepting it and adapting to the new normal….

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsOpinionPatient PerspectiveSpeak Out Rheum Tagged with:ACR Convergence 2022ACR Convergence 2022 – ASpatient perspective

Treat to Target in axSpA

Samantha C. Shapiro, MD  |  November 29, 2022

PHILADELPHIA—Treat to target (T2T) is a common phrase in rheumatology these days—and a welcome one.1 Many of us are familiar with what T2T means in rheumatoid arthritis (RA), but we may be less sure of its meaning in axial spondyloarthritis (axSpA). At ACR Convergence 2022, Alexis Ogdie, MD, associate professor of medicine and epidemiology, University of…

Filed under:Axial SpondyloarthritisConditionsMeeting Reports Tagged with:ACR Convergence 2022ACR Convergence 2022 – ASAS Resource CenteraxSpA

Is Gout an Autoinflammatory Syndrome After All?

Jason Liebowitz, MD, FACR  |  November 29, 2022

PHILADELPHIA—The term autoinflammatory syndrome was coined by Daniel L. Kastner, MD, PhD, National Institutes of Health (NIH), Bethesda, Md., not long after he discovered that mutations in the gene MEFV, which codes for the protein pyrin, are responsible for familial Mediterranean fever (FMF).1 Early on, the term was meant to signify monogenic conditions in which…

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2022ACR Convergence 2022 – GoutGout

Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022

Ruth Jessen Hickman, MD  |  November 28, 2022

PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…

Filed under:ACR ConvergenceConditionsMeeting ReportsSjögren’s DiseaseSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022DörnerLupusSjogren'sSLEsystemic lupus erythematous

Themes of Drama, Heroism & New Challenges Threaded President’s & Keynote Addresses at ACR Convergence 2022

Thomas R. Collins  |  November 18, 2022

PHILADELPHIA—Abraham Verghese, MD, best-selling author and infectious disease specialist, told a packed hall at the opening ceremony of ACR Convergence that he didn’t need to look far to find heroes not much different from the protagonists he has written about in his novels, which blend medical mystery with the passions and tragedies of human existence….

Filed under:Meeting Reports Tagged with:ACR Convergence 2022

Top Research in Axial Spondyloarthritis Presented at ACR Convergence 2022

David S. Pisetsky, MD, PhD  |  November 18, 2022

PHILADELPHIA—Approximately 100 research abstracts on axial spondyloarthritis (axSpA) were accepted for presentation at ACR Convergence 2022. It is exciting to see a wealth of research on axSpA being undertaken worldwide. Here, we highlight important points from 10 of these studies. 1. Abstract 0378: Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain…

Filed under:Axial SpondyloarthritisConditionsMeeting Reports Tagged with:ACR Convergence 2022ACR Convergence 2022 – ASAS Resource CenteraxSpA

Rheumatologist Organizes Medical Mission to Ukraine

Catherine Kolonko  |  November 10, 2022

Early in 2022, a few months into the invasion of Ukraine by Russian troops, Paula Rackoff, MD, a rheumatologist and clinical associate professor at NYU Grossman School of Medicine, New York, felt an urgency to head to the region to assist the many refugees fleeing for the border with Poland. Dr. Rackoff canceled a planned…

Filed under:Professional TopicsProfiles Tagged with:Disaster preparationVolunteering

  • « Previous Page
  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 243
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences